Kezar Life Sciences (KZR)
(Real Time Quote from BATS)
$0.63 USD
+0.01 (0.87%)
Updated Aug 16, 2024 11:50 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KZR 0.63 +0.01(0.87%)
Will KZR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KZR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KZR
Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce
Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?
KZR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech ETF Tops in June: 5 Stocks That Outperform
Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
Other News for KZR
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug
Kezar Life Sciences GAAP EPS of -$0.30
Kalamazoo’s Ashburton Gold Project Nears $33M Sale
Buy Rating Affirmed for Kezar Life Sciences Amidst Strong Clinical Progress and Strategic Focus
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Achieve Life Sciences (ACHV) and Kezar Life Sciences (KZR)